Cell Type-Dependent Pro- and Anti-Inflammatory Role of Signal Transducer and Activator of Transcription 3 in Alcoholic Liver Injury

Gastroenterology

Volumn 134, Issue 4, 2008, Pages 1148-1158

  Horiguchi, Norio ^a   Wang, Lei ^a   Mukhopadhyay, Partha ^a   Park, Ogyi ^a   Jeong, Won Il ^a   Lafdil, Fouad ^a   Osei Hyiaman, Douglas ^a   Moh, Akira ^b   Fu, Xin Yuan ^b   Pacher, Pál ^a   Kunos, George ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ALCOHOL; CHEMOKINE; CYTOKINE; FATTY ACID SYNTHASE; LIPOPOLYSACCHARIDE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ALCOHOL LIVER CIRRHOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TYPE; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; HYPERTRIGLYCERIDEMIA; KUPFFER CELL; LIVER CELL; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

EID: 41349098793     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.01.016     Document Type: Article

References (51)

1. Zakhari S., and Li T.K. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology 46 (2007) 2032-2039
2. Williams R. Global challenges in liver disease. Hepatology 44 (2006) 521-526
3. Tsukamoto H., and Lu S.C. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 15 (2001) 1335-1349
4. Dey A., and Cederbaum A.I. Alcohol and oxidative liver injury. Hepatology 43 (2006) S63-S74
5. Gramenzi A., Caputo F., Biselli M., et al. Review article: alcoholic liver disease-pathophysiological aspects and risk factors. Aliment Pharmacol Ther 24 (2006) 1151-1161
6. Arteel G.E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 124 (2003) 778-790
7. Hoek J.B., and Pastorino J.G. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 27 (2002) 63-68
8. Nagy L.E. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 228 (2003) 882-890
9. Uesugi T., Froh M., Arteel G.E., et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 168 (2002) 2963-2969
10. Yin M., Wheeler M.D., Kono H., et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 (1999) 942-952
11. Ji C., Deng Q., and Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 40 (2004) 442-451
12. You M., Considine R.V., Leone T.C., et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42 (2005) 568-577
13. Xu A., Wang Y., Keshaw H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
14. Hong F., Kim W.H., Tian Z., et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene 21 (2002) 32-43
15. Hong F., Radaeva S., Pan H.N., et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40 (2004) 933-941
16. Sun Z., Klein A.S., Radaeva S., et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 125 (2003) 202-215
17. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2 (2005) 92-100
18. Streetz K.L., Tacke F., Leifeld L., et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 38 (2003) 218-229
19. Alonzi T., Maritano D., Gorgoni B., et al. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 21 (2001) 1621-1632
20. Li W., Liang X., Kellendonk C., et al. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 277 (2002) 28411-28417
21. Yeoh G.C., Ernst M., Rose-John S., et al. Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology 45 (2007) 486-494
22. Haga S., Terui K., Zhang H.Q., et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 112 (2003) 989-998
23. Klein C., Wustefeld T., Assmus U., et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 115 (2005) 860-869
24. Streetz K.L., Wustefeld T., Klein C., et al. Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology 125 (2003) 532-543
25. Inoue H., Ogawa W., Ozaki M., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10 (2004) 168-174
26. Larrea E., Aldabe R., Molano E., et al. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 55 (2006) 1188-1196
27. Horiguchi N., Ishac E.J., and Gao B. Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol 41 (2007) 271-280
28. Welte T., Zhang S.S., Wang T., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 100 (2003) 1879-1884
29. Takeda K., Clausen B.E., Kaisho T., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999) 39-49
30. You M., Fischer M., Deeg M.A., et al. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 277 (2002) 29342-29347
31. Enomoto N., Schemmer P., Ikejima K., et al. Long-term alcohol exposure changes sensitivity of rat Kupffer cells to lipopolysaccharide. Alcohol Clin Exp Res 25 (2001) 1360-1367
32. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
33. Ji C., Chan C., and Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol 45 (2006) 717-724
34. Shimano H., Horton J.D., Hammer R.E., et al. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98 (1996) 1575-1584
35. Ueki K., Kondo T., Tseng Y.H., et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101 (2004) 10422-10427
36. Gao B. Therapeutic potential of interleukin-6 in preventing obesity- and alcohol-associated fatty liver transplant failure. Alcohol 34 (2004) 59-65
37. Roglans N., Vila L., Farre M., et al. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 45 (2007) 778-788
38. Pritchard M.T., McMullen M.R., Stavitsky A.B., et al. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 132 (2007) 1117-1126
39. Okada S., Nakamura M., Mikami Y., et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res 76 (2004) 265-276
40. Izumi-Nagai K., Nagai N., Ozawa Y., et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 170 (2007) 2149-2158
41. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40 (2004) 185-194
42. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (2007) 1366-1374
43. Maeda S., Kamata H., Luo J.L., et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
44. Gordon S., and Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5 (2005) 953-964
45. Pfitzner E., Kliem S., Baus D., et al. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 10 (2004) 2839-2850
46. Sakamori R., Takehara T., Ohnishi C., et al. Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice. Hepatology 46 (2007) 1564-1573
47. Kano A., Wolfgang M.J., Gao Q., et al. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med 198 (2003) 1517-1525
48. Ishihara K., and Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13 (2002) 357-368
49. Moore K.W., de Waal Malefyt R., Coffman R.L., et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
50. Shen X., Hong F., Nguyen V.A., et al. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 480 (2000) 132-136
51. Starkel P., De Saeger C., Leclercq I., et al. Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J Hepatol 43 (2005) 687-695